Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Dong‐Wan Kim et al.|New England Journal of Medicine|2013Cited by 3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, D. Ross Camidge et al.|New England Journal of Medicine|2017Cited by 2.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisJustin F. Gainor, Mari Mino–Kenudson, Alice T. Shaw et al.|Clinical Cancer Research|2016Cited by 1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor CellsEmre Ozkumur, Mehmet Toner, Ajay M. Shah et al.|Science Translational Medicine|2013Cited by 1.1k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Benjamin Solomon, Anna Polli et al.|New England Journal of Medicine|2020Cited by 1.1k